As we all know, whether in developed or developing countries, the incidence and mortality of acute kidney injury (AKI) are increasing year by year. At present, renal replacement therapy (RRT) is one of the effective methods for the treatment of AKI, and it is up to the clinician to make a decision when to carry out RRT. However, the emergence of Nicotinamide Mononucleotide (NMN) has brought new ideas for the treatment of this disease.

China's top scientific research institution Peking University has published the latest scientific research results on NMN: NMN administration may become an effective strategy for the prevention and treatment of AKI renal fibrosis. That is, the experiment of Peking University Institute of Nephrology found that NMN can significantly inhibit the DNA sequence, aging and inflammatory symptoms of renal tubular cells, which means that NMN has a significant effect on the treatment of kidney injury.

The latest experimental results show that the administration of NMN (NAD+precursor) can reduce the DNA damage and cell senescence of human renal tubular cells (HK-2 cells).

Our company can provide a large amount of pure NMN raw materials, and its main competitive advantage is safety and high purity. Our NMN has been tested by Chinese national laboratories and American Micro Quality Labs, and the purity can reach more than 99%.